general transcription factor IIE subunit 1Genealiases: FE · TF2E1 · TFIIE-A
Q-omics provides the consensus-scored GTF2E1 profile across patient tissues and cancer cell-line models. GTF2E1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GTF2E1 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, GTF2E1 protein abundance shows 22,295 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where GTF2E1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF2E1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF2E1 survival associations across molecular data types. GTF2E1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF2E1 RNA expression–survival associations across cancer types. High GTF2E1 expression shows unfavorable associations in ACC, LIHC and MESO, but favorable associations in KIRC, BRCA and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GTF2E1 RNA expression.
This table summarizes GTF2E1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GTF2E1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF2E1 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LIHC, COAD and KIRP. The HNSC box plot shows higher GTF2E1 RNA expression in tumor versus normal tissue (log2 FC = +1.238, t-test p < 0.001).
This table shows molecular features associated with GTF2E1 in patient tissues and cancer cell lines. In patient samples, GTF2E1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GTF2E1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
